Granules India vs Shilpa Medicare: Share Price, PE and ROE Compared
- August 13, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Granules India MCap Rs 21,437 Cr, PE 32.36x, ROE 11.70%. Shilpa Medicare MCap Rs 15,732 Cr, PE 52.92x, ROE 9.39%.
Quick Answer
Granules India and Shilpa Medicare are both mid-cap pharma companies. Granules at Rs 21,437 Cr trades at PE 32.36x with ROE 11.70%. Shilpa at Rs 15,732 Cr is priced higher at PE 52.92x with lower ROE of 9.39%, reflecting market expectations for its oncology and injectables pipeline.
The Granules India vs Shilpa Medicare question comes up often among investors who follow the Pharmaceuticals space in India. Granules India MCap Rs 21,437 Cr, PE 32. 36x, ROE 11. This article goes through what each company does, their latest financial performance, and the key numbers that matter for anyone evaluating Granules India vs Shilpa Medicare as a research exercise.
All data cited here is sourced from publicly available company filings. Verify the latest prices and fundamentals on NSE or BSE before acting on any information.
Granules India vs Shilpa Medicare: Company Overview and Market Presence
Granules India operates in the Pharmaceuticals segment and is listed on Indian exchanges. Granules India MCap Rs 21,437 Cr, PE 32 The company has built its market position over the years through its core offerings to customers across India.
Click Here – Get Free Investment Predictions
Shilpa Medicare is the other side of this Granules India vs Shilpa Medicare comparison. 36x, ROE 11 It competes in the same Pharmaceuticals space, though its scale and strategy may differ significantly from Granules India’s approach.
When investors look at the Granules India vs Shilpa Medicare pair, market capitalisation is usually the first filter. Granules India MCap Rs 21,437 Cr, PE 32. 36x, ROE 11. The size difference, if any, tells you something about liquidity and institutional ownership patterns.
Granules India vs Shilpa Medicare: Business Mix and Revenue Sources
To understand the Granules India vs Shilpa Medicare comparison fully, you need to look at how each company makes money. Granules India’s revenue comes from its core Pharmaceuticals operations. Granules India earns from the Pharmaceuticals segment.
Shilpa Medicare similarly derives its earnings from the Pharmaceuticals space. Shilpa Medicare operates in the Pharmaceuticals space. The product or service mix of the two companies can be similar or quite different depending on which subsegments each one serves.
Granules India vs Shilpa Medicare: Financial Results and Key Ratios
This is where the Granules India vs Shilpa Medicare comparison gets concrete. Return on equity, price-to-earnings ratio and market capitalisation are three metrics that help frame the relative position of each stock.
Granules India MCap Rs 21,437 Cr, PE 32 The profitability and efficiency ratios here reflect the latest available data from public filings.
36x, ROE 11 Both sets of numbers should be cross-checked against the latest quarterly reports from BSE or NSE before drawing any conclusions.
Compare Granules India and Shilpa Medicare on the Univest Screener
Granules India vs Shilpa Medicare: Valuation and What the Market Is Pricing In
Valuation is a core part of any Granules India vs Shilpa Medicare analysis. A high PE ratio can signal growth expectations or thin earnings. A low PE may indicate value or a business under stress. Neither is automatically good or bad without context.
Granules India MCap Rs 21,437 Cr, PE 32.36x, ROE 11.70%. Shilpa Medicare MCap Rs 15,732 Cr, PE 52.92x, ROE 9.39%. The Granules India vs Shilpa Medicare stock data above reflects figures sourced from publicly available data. Prices change daily, so treat this as a starting point for your own research rather than a definitive trading signal.
Dividend yield is another data point worth checking in the Granules India vs Shilpa Medicare pair. Some investors prioritise income alongside capital appreciation, and a consistent dividend track record can be a sign of earnings quality and management confidence in the cash flow.
Granules India vs Shilpa Medicare: Side-by-Side Comparison
The table below captures the most relevant metrics side by side for the Granules India vs Shilpa Medicare comparison.
| Parameter | Granules India | Shilpa Medicare |
|---|---|---|
| MCap | Rs 21,437 Cr | Rs 15,732 Cr |
| PE | 32.36x | 52.92x |
| ROE | 11.70% | 9.39% |
What Should Investors Know About the Granules India vs Shilpa Medicare Choice
Every Granules India vs Shilpa Medicare research exercise should go beyond just looking at the current share price. The sector outlook for Pharmaceuticals companies, the trajectory of earnings growth, debt levels and management quality all feed into a complete picture.
For the Granules India vs Shilpa Medicare pair specifically: Granules India MCap Rs 21,437 Cr, PE 32. 36x, ROE 11. These numbers are a starting point. Investors should also look at the trend over four to eight quarters rather than just the latest standalone figure, since one strong quarter does not always reflect the underlying business quality.
If you are building a portfolio allocation decision around the Granules India vs Shilpa Medicare comparison, consider the risk profile of your overall portfolio first. Both companies operate in Pharmaceuticals, which carries its own sector-specific risks including regulatory changes, commodity cost pressure, competitive intensity and macroeconomic sensitivity.
Conclusion
The Granules India vs Shilpa Medicare comparison comes down to this: Granules India and Shilpa Medicare are both listed Indian companies in the Pharmaceuticals space, but they differ in scale, valuation, and financial profile. Granules India MCap Rs 21,437 Cr, PE 32. 36x, ROE 11.
Granules India MCap Rs 21,437 Cr, PE 32.36x, ROE 11.70%. Shilpa Medicare MCap Rs 15,732 Cr, PE 52.92x, ROE 9.39%. Before taking any position in either stock, verify the latest fundamentals on NSE or BSE and consult a SEBI-registered investment advisor (registration number INH000013776).
Download the Univest iOS App or Univest Android App to track Granules India and Shilpa Medicare live and get analyst-backed stock recommendations every day.
Disclaimer: Data and figures in this article are sourced from publicly available information and may not be fully accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice from Univest (SEBI RA INH000013776).
Frequently Asked Questions
What does Granules India do?
Ans. Granules India is a listed Indian company in the Pharmaceuticals segment. For the latest business updates, visit univest.in.
What does Shilpa Medicare do?
Ans. Shilpa Medicare is a listed Indian company in the Pharmaceuticals segment. For the latest business updates, visit univest.in.
Which is larger in the Granules India vs Shilpa Medicare comparison?
Ans. Based on current market cap data: Granules India MCap Rs 21,437 Cr, PE 32. Verify the latest figures on NSE or BSE.
How do PE ratios compare in Granules India vs Shilpa Medicare?
Ans. The PE ratio comparison is covered in the data table above. Verify current figures from NSE or BSE before investing.
What is the ROE of Granules India?
Ans. The ROE of Granules India is mentioned in the data table above. Verify from the latest quarterly filings.
Does Shilpa Medicare pay dividends?
Ans. Dividend yield information for Shilpa Medicare is included in the comparison above. Verify from NSE or BSE.
How should I evaluate Pharmaceuticals stocks?
Ans. For Pharmaceuticals stocks, review earnings quality, ROE trends, debt levels and sector outlook. Consult a SEBI-registered advisor (INH000013776) before investing.
